Brought to you by 
BI signs ten-target DART alliance with MacroGenics
30 Jan 2023
Executive Summary
In one of two Big Pharma deals it signed on the same day, biologics developer MacroGenics Inc. has agreed to work with Boehringer Ingelheim GMBH on antibody-like molecules against up to ten combinations of targets, initially for immune disorders and potentially extending to cancer and respiratory, cardio-metabolic, and infectious diseases. The candidates will be generated by MacroGenics' Dual-Affinity Re-Targeting (DART) technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BI signs ten-target DART alliance with MacroGenics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice